We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Pea8.5
PEA Research
Likely helpsHigh safety
37 peer-reviewed studies
What the evidence says
Likely helps
PEA appears to help in 7 of 7 studies with measurable effects — the evidence leans clearly favourable.
Most evidence is from high-quality meta-analyses and randomised trials published 2016–2026 with a typical study size of 60 participants.
Based on 37 studies · 9 meta-analyses · 16 RCTs · 8,911 total participants
Confidence
High
What the studies found
7helped· 30 more without graded effect data
By outcome
Pain & analgesia
Likely helps29 studies
Therapeutic & clinical
Mostly mechanism / observational13 studies
Safety profile
Likely helps7 studies
InflammationSignificant reduction in chronic pain · 2-8 weeks
Mostly mechanism / observational6 studies
Cognitive function
Mostly mechanism / observational4 studies
Women's healthMay help reduce menstrual discomfort and PMS symptoms · 1-3 cycles
Mostly mechanism / observational3 studies
Joint pain & arthritisReduced joint pain and inflammation within 2-4 weeks · 2-4 weeks
Mostly mechanism / observational3 studies
Immune support
Mostly mechanism / observational3 studies
Anxiety & stress
Too few graded studies1 study
Digestive health
Too few graded studies1 study
Glucose & metabolic
Too few graded studies1 study
By the numbers
Pulled from 27 studies with measurable effects
Likely real effects
100%
across studies
People studied
8,911
typical study: 60 people
Strongest designs
25
9 pooled, 16 randomised
Showed benefit
100%
7/7 studies
How long studies ran
1–3 months
4
3+ months
4
Populations Studied
Chronic pain patients2
Children and adults with ASD or ID1
Pain patients1
Normal tension glaucoma patients1
Active research area
30 studies in the last 5 years · Latest meta-analysis: 2025
201620212026
1Pain scoresMeta-AnalysisCited 41×n=774 · large study2023
Further study is warranted to determine the optimal dosing and administration parameters of PEA for analgesic effects in the context of chronic pain.
Lang-Illievich K et al. · Nutrients (2023)
Huge benefit
← WorseNo effectBetter →
Likely real
PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001).
Several studies reported additional benefits of PEA for quality of life and functional status, and no major side effects were attributed to PEA in any study.
The results of this systematic review and meta-analysis suggest that PEA is an effective and well-tolerated treatment for chronic pain.
2Agitation managementMeta-AnalysisCited 2×n=2,503 · very large study2025
This study underscores the efficacy and tolerability of several pharmacotherapies in managing agitation among children and adults with ASD or ID.
Bahji A et al. · Journal of psychopharmacology (Oxford, England) (2025)
Importantly, these treatments were generally well-tolerated, with no significant increase in all-cause dropouts compared to placebo, highlighting their suitability for clinical use in managing agitation in individuals with ASD or ID.
This study underscores the efficacy and tolerability of several pharmacotherapies in managing agitation among children and adults with ASD or ID.
Our findings provide robust evidence that specific treatments, such as arbaclofen, risperidone plus buspirone and omega-3 fatty acids, are both effective and well-tolerated, offering valuable therapeutic options for clinicians.
3Pain reduction and quality of lifeMeta-AnalysisCited 1×n=1,196 · large study2025
This meta-analysis confirmed that PEA effectively reduces pain and enhances quality of life, with significant benefits observed within 4-6 weeks of treatment.
Viña I et al. · Nutrition reviews (2025)
This meta-analysis confirmed that PEA effectively reduces pain and enhances quality of life, with significant benefits observed within 4-6 weeks of treatment.
Palmitoylethanolamide is a promising alternative to chronic opioid analgesics, potentially reducing the risk of opioid abuse and dependency.
5Pain intensity reductionMeta-AnalysisCited 10×n=742 · large study2024
Overall, these results confirm the clinically relevant and time-depended pain-relieving effect of micron-size PEA and therefore the advantage of an extended treatment, especially in patient with incomplete pain management.
Schweiger V et al. · Nutrients (2024)
Huge benefit
← WorseNo effectBetter →
Likely real
These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month.
The meta-analysis showed a statistically and clinically significant pain intensity reduction after 60 days of micron-size PEA supplementation, compared to 30 days (1.36 points, p < 0.01).
The secondary analysis revealed a weighted NRS/VAS score decrease of 2.08 points within the first month of treatment.
PEA may be a useful treatment for pain and is generally well tolerated in research populations.
Artukoglu BB et al. · Pain physician (2017)
PEA was associated with significantly greater pain reduction compared to inactive control conditions (WMD = 2.03, 95% CI: 1.19 - 2.87, z = 4.75, P < 0.001).
All-cause dropout was non-significantly reduced in the PEA group compared to inactive control conditions (RR = 0.36, 95% CI: 0.10 - 1.26, z = -1.60, P = 0.11).
PEA may be a useful treatment for pain and is generally well tolerated in research populations.
Treatments such as PRP and calcium chelators demonstrated significant improvements on OFS, whereas olfactory training and corticosteroids did not show notable efficacy for COVID-19 associated olfactory dysfunction.
Bischoff S et al. · Current allergy and asthma reports (2024)
9Brain fog symptoms improvementSystematic ReviewCited 19×n=17 · very small study2024
This systematic-review examined the effects of Luteolin.
Gorenshtein A et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024)
Noninvasive brain stimulation and hyperbaric oxygen therapy showed promising results in the treatment of brain fog symptoms caused by long-COVID, with improved perfusion and cortical excitability.
Furthermore, both rehabilitation strategies and PEA-LUT administration have been associated with improvements in symptoms of brain fog.
Future studies should explore combinations of interventions and include longer follow-up periods to assess the long-term effects of these treatments.
11Adverse eventsSystematic ReviewCited 46×n=20 · very small study2022
There is very low certainty evidence that adverse events are common among people living with chronic pain who use medical cannabis or cannabinoids, but that few patients experience serious adverse events.
Zeraatkar D et al. · BMJ open (2022)
Large benefit
← WorseNo effectBetter →
Very low certainty evidence suggests that adverse events are common (prevalence: 26.0%; 95% CI 13.2% to 41.2%) among users of medical cannabis for chronic pain, particularly any psychiatric adverse events (prevalence: 13.5%; 95% CI 2.6% to 30.6%).
There is very low certainty evidence that adverse events are common among people living with chronic pain who use medical cannabis or cannabinoids, but that few patients experience serious adverse events.
Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation.
Colizzi M et al. · Nutrients (2021)
Stress and exposure to exogenous cannabinoids may modulate ECBs/AEs levels and expression of candidate genes for neuropsychiatric disorders, with implications for ASD.
Limited research suggests that PEA supplementation reduces overall autism severity by improving language and social and nonsocial behaviors.
13Systematic ReviewCited 5×n=11 · very small study2024
Mast cell modulating therapies could be of significant value in therapy for IBS patients.
Coppens D et al. · Acta gastro-enterologica Belgica (2024)
Mast cell modulating therapies could be of significant value in therapy for IBS patients.
Further high-quality research is needed to establish the therapeutic efficacy of mast cell targeted therapies in order to draw robust conclusions and improve the clinical management of irritable bowel syndrome.
Evidence was collected from highly biased, short-term, heterogenous studies mainly focused on BMS-related pain, with scarce data on quality of life, psychologic status, dysgeusia, and xerostomia.
Cabras M et al. · Journal of oral & facial pain and headache (2021)
Evidence was collected from highly biased, short-term, heterogenous studies mainly focused on BMS-related pain, with scarce data on quality of life, psychologic status, dysgeusia, and xerostomia.
Long-term effectiveness of nonpharmacologic treatments should be further investigated, with a more rigorous, bias-proof study design.
In this review the large number of studies on the benefits derived from oral administration of micronized and highly bioavailable forms of Palmitoylethanolamide is discussed, with special reference to neuroinflammatory disorders.
Petrosino S et al. · International journal of molecular sciences (2020)
It has been shown that the regulation of non-neuronal cells-and therefore the control of neuroinflammation-depends on the local "on demand" synthesis of the endogenous lipid amide Palmitoylethanolamide and related endocannabinoids.
When the balance between synthesis and degradation of this bioactive lipid mediator is disrupted in favor of reduced synthesis and/or increased degradation, the behavior of non-neuronal cells may not be appropriately regulated and neuroinflammation exceeds the physiological boundaries.
In this review the large number of studies on the benefits derived from oral administration of micronized and highly bioavailable forms of Palmitoylethanolamide is discussed, with special reference to neuroinflammatory disorders.
These results confirm that PEA might represent an exciting, new therapeutic strategy to manage chronic and neuropathic pain associated with neuroinflammation.
Paladini A et al. · Pain physician (2016)
Huge benefit
← WorseNo effectBetter →
The magnitude of reduction equals 1.04 points every 2 weeks with a 35% response variance explained by the linear model.
In contrast, in the control group pain, reduction intensity equals 0.20 points every 2 weeks with only 1% of the total variance explained by the regression.
The Kaplan-Meier estimator showed a pain score = 3 in 81% of PEA treated patients compared to only 40.9% in control patients by day 60 of treatment.
20Olfactory recoveryRCTCited 76×n=185 · medium study2022
Among individuals with olfactory dysfunction post-COVID-19, combining PEA-LUT with olfactory training resulted in greater recovery of smell than olfactory training alone.
Di Stadio A et al. · Current neuropharmacology (2022)
Huge benefit
← WorseNo effectBetter →
Likely real
The intervention group showed significantly greater improvement in olfactory threshold, discrimination, and identification scores compared to controls (p=0.0001).
Overall, 92% of patients in the intervention group improved versus 42% of controls.
Magnitude of recovery was significantly greater in the intervention group versus control (12.8 + 8.2 versus mean 3.2 + 3), with >10-fold higher prevalence of anosmia in control versus intervention groups at the 90-day endpoint.